Kathryn M. Rexrode

Kathryn M. Rexrode

Top Cited Scholar 2025
Auto-generated profile, based on publicly available information

Kathryn M. Rexrode

Brigham and Women’s Hospital and Harvard Medical School

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2018 in Nature Genetics
Verified
Journal Article
Open access
PDF file
RMRainer Malik
Rainer Malik
GCGanesh Chauhan
Ganesh Chauhan
MTMatthew Traylor
Matthew Traylor
MSMuralidharan Sargurupremraj
Muralidharan Sargurupremraj
YOYukinori Okada
Yukinori Okada
MDMartin Dichgans
Martin Dichgans
Stroke has multiple etiologies, but the underlying genes and pathways are largely unknown. We conducted a multiancestry genome-wide-association meta-analysis in 521,612 individuals (67,162 cases and 454,450 controls) and discovered 22 new stroke risk loci, bringing the total to 32. We further found shared genetic variation with related vascular traits, including blood pressure, cardiac traits, and venous thromboembolism, at individual loci (n = 18), and using genetic risk scores and linkage-disequilibrium-score regression. Several loci exhibited distinct association and pleiotropy patterns for etiological stroke subtypes. Eleven new susceptibility loci indicate mechanisms not previously implicated in stroke pathophysiology, with prioritization of risk variants and genes accomplished through bioinformatics analyses using extensive functional datasets. Stroke risk loci were significantly enriched in drug targets for antithrombotic therapy.

14 April 2008 in Archives of internal medicine (1960)
Verified
Journal Article
Closed access
PDF file
TFTeresa T. Fung
Teresa T. Fung
SCStephanie E. Chiuve
Stephanie E. Chiuve
MMMarjorie L. McCullough
Marjorie L. McCullough
KRKathryn M. Rexrode
Kathryn M. Rexrode
GLGiancarlo Logroscino
Giancarlo Logroscino
FHFrank B. Hu
Frank B. Hu
Research from JAMA Internal Medicine — Adherence to a DASH-Style Diet and Risk of Coronary Heart Disease and Stroke in Women

1 July 2017 in JACC
Verified
Journal Article
Closed access
ASAmbika Satija
Ambika Satija
SBShilpa N. Bhupathiraju
Shilpa N. Bhupathiraju
DSDonna Spiegelman
Donna Spiegelman
SCStephanie E. Chiuve
Stephanie E. Chiuve
JMJoAnn E. Manson
JoAnn E. Manson
FHFrank B. Hu
Frank B. Hu

20 April 2007 in BMJ
Verified
Journal Article
Closed access
PDF file
NCNancy R Cook
Nancy R Cook
JCJeffrey A Cutler
Jeffrey A Cutler
EOEva Obarzanek
Eva Obarzanek
JBJulie E Buring
Julie E Buring
KRKathryn M Rexrode
Kathryn M Rexrode
PWPaul K Whelton
Paul K Whelton
Objective To examine the effects of reduction in dietary sodium intake on cardiovascular events using data from two completed randomised trials, TOHP I and TOHP II.Design Long term follow-up assessed 10-15 years after the original trial.Setting 10 clinic sites in 1987-90 (TOHP I) and nine sites in 1990-5 (TOHP II). Central follow-up conducted by post and phone.Participants Adults aged 30-54 years with prehypertension.Intervention Dietary sodium reduction, including comprehensive education and counselling on reducing intake, for 18 months (TOHP I) or 36-48 months (TOHP II).Main outcome measure Cardiovascular disease (myocardial infarction, stroke, coronary revascularisation, or cardiovascular death).Results 744 participants in TOHP I and 2382 in TOHP II were randomised to a sodium reduction intervention or control. Net sodium reductions in the intervention groups were 44 mmol/24 h and 33 mmol/24 h, respectively. Vital status was obtained for all participants and follow-up information on morbidity was obtained from 2415 (77%), with 200 reporting a cardiovascular event. Risk of a cardiovascular event was 25% lower among those in the intervention group (relative risk 0.75, 95% confidence interval 0.57 to 0.99, P=0.04), adjusted for trial, clinic, age, race, and sex, and 30% lower after further adjustment for baseline sodium excretion and weight (0.70, 0.53 to 0.94), with similar results in each trial. In secondary analyses, 67 participants died (0.80, 0.51 to 1.26, P=0.34).Conclusion Sodium reduction, previously shown to lower blood pressure, may also reduce long term risk of cardiovascular events.

2 December 1998 in JAMA
Verified
Journal Article
Open access
PDF file
KRKathryn M. Rexrode
Kathryn M. Rexrode
VCVincent J. Carey
Vincent J. Carey
CHCharles H. Hennekens
Charles H. Hennekens
EWEllen E. Walters
Ellen E. Walters
GCGraham A Colditz
Graham A Colditz
JMJoAnn E. Manson
JoAnn E. Manson
OBESITY is well recognized as a major risk factor for coronary heart disease (CHD) in men and women.1-3 However, since Vague's4 description of the association between upper body obesity and cardiovascular disease, the relative importance of total and regional obesity has been debated. Abdominal adiposity has been linked to significant metabolic abnormalities, including insulin resistance, hyperinsulinemia, and elevated triglyceride levels, as well as increased incidence of hypertension,5 glucose intolerance,6 and diabetes mellitus.7 Several studies suggest that abdominal adiposity, as measured by waist-hip ratio (WHR), is an independent risk factor for CHD in men8,9 and perhaps also in women.10,11 Waist circumference has also been associated with increased risk of CHD9,12 and has been advocated by some as a simpler measure of abdominal obesity.13 However, whether regional obesity remains a risk factor after taking total adiposity into account remains controversial. The purpose of this study was to determine the risk of CHD associated with abdominal adiposity in women and to compare the effects of WHR and waist circumference.

1 May 2014 in Stroke
Verified
Journal Article
Closed access
PDF file
CBCheryl Bushnell
Cheryl Bushnell
LMLouise D. McCullough
Louise D. McCullough
IAIssam A. Awad
Issam A. Awad
MCMonique V. Chireau
Monique V. Chireau
WFWende N. Fedder
Wende N. Fedder
MWMatthew R. Walters
Matthew R. Walters
Purpose—The aim of this statement is to summarize data on stroke risk factors that are unique to and more common in women than men and to expand on the data provided in prior stroke guidelines and cardiovascular prevention guidelines for women. This guideline focuses on the risk factors unique to women, such as reproductive factors, and those that are more common in women, including migraine with aura, obesity, metabolic syndrome, and atrial fibrillation. Methods—Writing group members were nominated by the committee chair on the basis of their previous work in relevant topic areas and were approved by the American Heart Association (AHA) Stroke Council’s Scientific Statement Oversight Committee and the AHA’s Manuscript Oversight Committee. The panel reviewed relevant articles on adults using computerized searches of the medical literature through May 15, 2013. The evidence is organized within the context of the AHA framework and is classified according to the joint AHA/American College of Cardiology and supplementary AHA Stroke Council methods of classifying the level of certainty and the class and level of evidence. The document underwent extensive AHA internal peer review, Stroke Council Leadership review, and Scientific Statements Oversight Committee review before consideration and approval by the AHA Science Advisory and Coordinating Committee. Results—We provide current evidence, research gaps, and recommendations on risk of stroke related to preeclampsia, oral contraceptives, menopause, and hormone replacement, as well as those risk factors more common in women, such as obesity/metabolic syndrome, atrial fibrillation, and migraine with aura. Conclusions—To more accurately reflect the risk of stroke in women across the lifespan, as well as the clear gaps in current risk scores, we believe a female-specific stroke risk score is warranted.